Core Viewpoint - The issuance of an executive order by President Donald Trump to reschedule cannabis from Schedule I to Schedule III under the U.S. Controlled Substances Act is a significant development for the cannabis industry, enhancing operational economics and enabling expanded medical research [2][3]. Company Summary - LEEF Brands, Inc. is a leading multi-state operator in the cannabis industry, focusing on extraction, manufacturing, and cultivation, with operations in California and New York [6]. - The rescheduling of cannabis to Schedule III will eliminate the 280E tax burden, improving cash flow and allowing LEEF to reinvest in its workforce, facilities, and long-term growth [3]. - The company operates state-of-the-art extraction and cultivation facilities and believes that the removal of 280E will strengthen balance sheets across the sector, providing more growth capital for expansion [3][4]. Industry Summary - The rescheduling of cannabis is expected to improve access to capital across the cannabis industry, potentially attracting institutional investors and broadening the pool of available lenders [4]. - Improved regulatory clarity may lower the overall cost of capital, creating opportunities for companies to fund growth and scale operations more efficiently [4]. - LEEF is also monitoring developments related to hemp-derived cannabinoids and potential Medicare coverage for certain CBD products, with a pilot program expected as early as 2026 [4].